Results 331 to 340 of about 3,108,169 (356)
Some of the next articles are maybe not open access.
Future Advances in Melanoma Research
Clinics in Plastic Surgery, 2010 The future of melanoma research is promising. Specific mechanisms leading to oncogenic transformation in melanoma development have been identified, and are likely to produce new targets for melanoma therapy. Also, advances in melanoma research will result from melanoma investigators co-opting approaches used to study other malignancies in which ...openaire +2 more sourcesNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
The Lancet Oncology, 2015 Jeffrey S. Weber, S. D’Angelo, D. Minor, F. Hodi, R. Gutzmer, B. Neyns, C. Hoeller, N. Khushalani, Wilson H. Miller, C. Lao, G. Linette, L. Thomas, P. Lorigan, K. Grossmann, J. Hassel, M. Maio, M. Sznol, P. Ascierto, P. Mohr, B. Chmielowski, A. Bryce, I. Svane, J. Grob, Angela M. Krackhardt, C. Horak, A. Lambert, A. Yang, J. Larkin +27 moresemanticscholar +1 more sourcePembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
The Lancet, 2017 J. Schachter, A. Ribas, G. Long, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. Blank, T. Petrella, O. Hamid, Honghong Zhou, S. Ebbinghaus, N. Ibrahim, C. Robert +19 moresemanticscholar +1 more sourceSafety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
Journal of Clinical Oncology, 2017 J. Weber, F. Hodi, J. Wolchok, S. Topalian, D. Schadendorf, J. Larkin, M. Sznol, G. Long, Hewei Li, I. Waxman, Joel Jiang, C. Robert +11 moresemanticscholar +1 more source
